High-Flying Biotech Stock 360% Faces Trim, Top Holding
A biotech stock that jumped 360% for investors is dealing with a big fund trim while staying the largest holding. Thi...
Understanding the value of points versus cash back helps you make smart financial choices. Compare both to see which is more beneficial.
28,655 articlesA biotech stock that jumped 360% for investors is dealing with a big fund trim while staying the largest holding. Thi...
What if you could cap downside risk while preserving upside potential? This deep dive shares how defined outcome inve...
UBS analysts view Target's planned $2 billion investment for 2026 as a bold, two-pronged turnaround bet. The plan spl...
When a top investor adds to a position after a selloff, it can reveal confidence not just in a single company, but in...
Ring CEO Jamie Siminoff says more home cameras could help investigators, a stance that elevates the debate over secur...
A major air campaign demonstrated how layered airpower blends stealth, electronic warfare, and precision munitions. I...
A billionaire hedge fund manager shows the power of high-conviction bets in AI. This article breaks down Ackman'...
A notable move in a clean energy ETF raised questions: does a big sale signal trouble or discipline in a fast-growing...
Nebius is carving a niche in AI cloud services with data centers and ML software. This guide breaks down what buying ...
A stock delivering a 7% dividend yield and yet slipping 20% year-to-date may seem puzzling. This guide explains how t...
Cyclops, a Miami-based payments infrastructure startup, closed a $20 million Series A to accelerate settlement speeds...
XRP breached the $1 support, prompting a renewed look at downside risk and potential relief rallies. This article map...